Cohance Lifesciences Receives 4 FDA Form 483 Observations

Lifesciences received four FDA Form 483 observations following a plant inspection. This is worth reading directly alongside the Gland Pharma inspection we covered recently, that facility received zero observations from the FDA. Here's what actually happens on this other side of the outcome. 1. A Form 483 is a list of specific deficiencies inspectors observed, not a final penalty. It's issued at the end of an inspection when investigators identify conditions that may violate FDA regulations. Receiving one isn't the end of the process, it's the start of a formal response cycle. 2. The company now has to respond in writing, typically within 15 business days. Cohance would need to submit a corrective action plan addressing each of the four observations, explaining what will be fixed and by when. The FDA then reviews that response before deciding on further action. 3. Not every Form 483 leads to serious consequences. Outcomes range widely, some observations get resolved with minor procedural fixes and no further action, while more serious or repeated issues can escalate to a Warning Letter or import restrictions. Four observations, without knowing their specific severity, doesn't by itself tell you which outcome is likely here. An inspection with observations creates a period of genuine uncertainty, the business isn't necessarily disrupted yet, but the range of possible outcomes is now much wider than it was for a facility with a clean result. The takeaway: Not all FDA inspection outcomes are equal, and not all Form 483s are equally serious. The real story here plays out over the coming weeks, in Cohance's written response and the FDA's reaction to it, not in the observation count alone.